Drug

HutchMed's SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC
Academic conferenceCancer

HutchMed’s SANOVO Phase III Hits Primary Endpoint – ORPATHYS Plus TAGRISSO Extends Median PFS to 24.9 Months in MET-Overexpressing EGFR-Mutant NSCLC

HutchMed (China) Limited (NASDAQ: HCM; HKG: 0013) announced positive results from the SANOVO Phase III study in China, showing that ORPATHYS (savolitinib) in combination with TAGRISSO (osimertinib) demonstrated a statistically…

Astellas' Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Astellas’ Non-Hormonal VEOZA Gains NMPA NDA Acceptance for Menopausal Hot Flashes in China

Sino Biopharmaceutical's CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Sino Biopharmaceutical’s CTTQ Earns Dual CDE Breakthrough Therapy Designations for TQ-A3334 and TQA3605 in Chronic Hepatitis B

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
CirCode Biomed's Circular RNA Drug HM2002 Approved for US Clinical Trials
Circode BioCVD

CirCode Biomed’s Circular RNA Drug HM2002 Approved for US Clinical Trials

Bayer's Nubeqa Gets FDA Approval for mHSPC Treatment
BayerProduct approvals

Bayer’s Nubeqa Gets FDA Approval for mHSPC Treatment

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025
Academic conferenceCancer

Sino Biopharmaceutical Presents CAMPASS Phase III Results at ASCO 2025

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler
Lepu Medical TechnologyProduct approvals

Lepu Medical Wins NMPA Approval for Polylactic Acid Facial Filler

Show More